Patient Experiences With GLP-1 Receptor Agonists

What are the experiences of patients taking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and how can their experiences improve clinical care?This qualitative study involving thematic analysis of semistructured interviews with 30 participants found that patients using GLP-1 RAs experienced a substantial reduction in psychological hunger, a wide spectrum of adverse effects, and a willingness to tolerate adverse effects to achieve weight loss. External factors included variable care quality, perceived stigma, and access barriers.These findings suggest that GLP-1 RAs are not a standalone solution to weight loss but may facilitate increased agency over lifestyle changes, and that standardized guidelines for patient education and clinical support, alongside behavioral interventions, may improve long-term adherence and outcomes.

Corresponding Author: Isabella de Vere Hunt, MD, Nuffield Department of Primary Care Health Sciences, Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Rd, Oxford OX2 6GG, United Kingdom (Isabella.deverehunt@phc.ox.ac.uk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.